Literature DB >> 28960165

Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers.

Rahul Maheshwari1, Muktika Tekade2, Piyush Gondaliya1, Kiran Kalia1, Antony D'Emanuele3, Rakesh Kumar Tekade1.   

Abstract

RNA interference (RNAi) therapeutics (siRNA, miRNA, etc.) represent an emerging medicinal remedy for a variety of ailments. However, their low serum stability and low cellular uptake significantly restrict their clinical applications. Exosomes are biologically derived nanodimensional vesicle ranging from a few nanometers to a hundred. In the last few years, several reports have been published demonstrating the emerging applications of these exogenous membrane vesicles, particularly in carrying different RNAi therapeutics to adjacent or distant targeted cells. In this report, we explored the numerous aspects of exosomes from structure to clinical implications with special emphasis on their application in delivering RNAi-based therapeutics. siRNA and miRNA have attracted great interest in recent years due to their specific application in treating many complex diseases including cancer. We highlight strategies to obviate the challenges of their low bioavailability for gene therapy.

Entities:  

Keywords:  RNAi; clinical trials; exosomal proteins; exosomes; gene silencing; gene therapy; genetic diseases; nanocarriers; patents

Mesh:

Substances:

Year:  2017        PMID: 28960165     DOI: 10.2217/nnm-2017-0210

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  6 in total

Review 1.  New Approaches for Enhancement of the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cardiovascular Diseases.

Authors:  Lamiaa Ahmed; Khaled Al-Massri
Journal:  Tissue Eng Regen Med       Date:  2022-07-22       Impact factor: 4.451

Review 2.  Exosomes in Parkinson disease.

Authors:  Jennifer R Pinnell; Mei Cui; Kim Tieu
Journal:  J Neurochem       Date:  2021-01-22       Impact factor: 5.372

3.  Reduced expression of exosomal miR‑29s in peritoneal fluid is a useful predictor of peritoneal recurrence after curative resection of gastric cancer with serosal involvement.

Authors:  Hideyuki Ohzawa; Akira Saito; Yuko Kumagai; Yuki Kimura; Hironori Yamaguchi; Yoshinori Hosoya; Alan Kawarai Lefor; Naohiro Sata; Joji Kitayama
Journal:  Oncol Rep       Date:  2020-02-17       Impact factor: 3.906

4.  Efficient Delivery of Therapeutic siRNA by Fe3O4 Magnetic Nanoparticles into Oral Cancer Cells.

Authors:  Lili Jin; Qiuyu Wang; Jiayu Chen; Zixiang Wang; Hongchuan Xin; Dianbao Zhang
Journal:  Pharmaceutics       Date:  2019-11-17       Impact factor: 6.321

Review 5.  Stem Cell-Derived Exosome in Cardiovascular Diseases: Macro Roles of Micro Particles.

Authors:  Ye Yuan; Weijie Du; Jiaqi Liu; Wenya Ma; Lai Zhang; Zhimin Du; Benzhi Cai
Journal:  Front Pharmacol       Date:  2018-05-31       Impact factor: 5.810

Review 6.  The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.

Authors:  Simoneide S Titze-de-Almeida; Cristina Soto-Sánchez; Eduardo Fernandez; James B Koprich; Jonathan M Brotchie; Ricardo Titze-de-Almeida
Journal:  Cells       Date:  2020-03-31       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.